secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001999371-26-008771
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports preclinical data for TNX-1700 and TNX-4700 at AACR 2026
---------------------------------------------------------------------

- TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mouse model.
- TNX-1700 showed dose-independent linear PK in non-human primates and transgenic mice; no significant weight loss.
- TNX-4700 anti-BTLA mAbs demonstrated potent, high-affinity binding and functional antagonism in vitro.
- Three TNX-4700 antagonists had reduced FcgRI binding and no FcgRIIB binding, potentially lowering FcR-dependent toxicities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126008771/0001999371-26-008771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126008771/tnxp_8k-042226.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-008771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer